MORBIDITY AND MORTALITY WITHIN 30 DAYS OF SYSTEMIC ANTI-CANCER THERAPY - REVIEW OF CURRENT PRACTICE - STANDARDISED REVIEW PROCESS

The importance of having mortality meetings to review deaths within 30 days of treatment with SACT has been established and most trusts have developed their own system for deciding which cases to discuss. The UK Chemotherapy Board recognised the many current examples of good practice but noted an inconsistency of approach between centres which may limit sharing of learning. It has summarised the key details of the processes currently used and developed a proposed template for an operational policy and pro forma.

 

MORBIDITY AND MORTALITY WITHIN 30-DAYS OF SYSTEMIC ANTI-CANCER THERAPY (SACT): REVIEW OF CURRENT PRACTICE SUGGESTED STANDARDISED REVIEW PROCESS
MAY 2016

APPENDIX 3: PROPOSED 30 DAY SYSTEMIC ANTI-CANCER THERAPY (SACT) MORTALITY PROFORMA.

30 DAY SACT MORTALITY LETTER

 

©2020 by UK Chemotherapy Board